Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
0.7200
+0.0022 (0.31%)
May 23, 2025, 9:40 AM - Market open
Neumora Therapeutics Stock Forecast
NMRA's stock price has decreased by -92.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Neumora Therapeutics stock ranges from a low of $1.00 to a high of $20. The average analyst price target of $9.29 forecasts a 1,190.28% increase in the stock price over the next year.
Price Target: $9.29 (+1,190.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +594.44% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +594.44% | Apr 10, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $1 | Strong Buy → Sell | Downgrades | $7 → $1 | +38.89% | Apr 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $6 → $2 | Strong Buy → Hold | Downgrades | $6 → $2 | +177.78% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 290.13M
Revenue Next Year
n/a
EPS This Year
-1.53
from -1.53
EPS Next Year
-1.21
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | 42.0M | ||
| Avg | n/a | 3.6M | 10.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,052.9% | ||
| Avg | - | - | 177.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.30 | -0.62 | -0.49 | ||
| Avg | -1.53 | -1.21 | -1.21 | ||
| Low | -1.75 | -1.73 | -1.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.